These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 712115

  • 41. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.
    Vaccine; 2012 Jul 06; 30(32):4884-91. PubMed ID: 22537989
    [Abstract] [Full Text] [Related]

  • 42. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers.
    Webster A, Boyce M, Edmundson S, Miller I.
    Clin Pharmacokinet; 1999 Jul 06; 36 Suppl 1():51-8. PubMed ID: 10429840
    [Abstract] [Full Text] [Related]

  • 43. [A new influenza subunit vaccine: hemagglutinating antibodies one year after vaccination (author's transl)].
    Kunz C, Hofmann H, Moritz A, Bachmayer H, Liehl E.
    Infection; 1978 Jul 06; 6(5):217-20. PubMed ID: 365774
    [Abstract] [Full Text] [Related]

  • 44. Comparison of the hemagglutination-inhibiting and neutralizing antibody responses of volunteers given 400 chick cell-agglutinating units of influenza A/New Jersey/76 split-virus vaccine.
    Massicot J, Murphy BR.
    J Infect Dis; 1977 Dec 06; 136 Suppl():S472-4. PubMed ID: 606769
    [Abstract] [Full Text] [Related]

  • 45. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S, Nauta J, Montomoli E, Weckx J.
    Vaccine; 2018 Sep 25; 36(40):6030-6038. PubMed ID: 29709447
    [Abstract] [Full Text] [Related]

  • 46. Field trial of live attenuated influenza A/B ("Alice"/R-75) vaccine.
    Rytel MW, Jackson LJ, Niebojewski RA, Haagensen JL, Rosenkranz MA.
    Am J Epidemiol; 1977 Jan 25; 105(1):49-55. PubMed ID: 831465
    [Abstract] [Full Text] [Related]

  • 47. Antibody responses and resistance to challenge in volunteers vaccinated with live attenuated, detergent split and oil adjuvant A2-Hong Kong-68 (H 3 N 2 ) influenza vaccines. A report to the Medical Research Council Committee on Influenza and other Respiratory Virus Vaccines.
    Freestone DS, Hamilton-Smith S, Schild GC, Buckland R, Chinn S, Tyrrell DA.
    J Hyg (Lond); 1972 Sep 25; 70(3):531-43. PubMed ID: 4506997
    [Abstract] [Full Text] [Related]

  • 48. [Safety and immunogenicity of split vaccines of influenza viruses].
    Zhu CL, Fang HH, Zhu FC, Wang YQ, Wu XL, Xue FB, Shen YJ, Lian JZ.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep 25; 18(3):207-9. PubMed ID: 15640848
    [Abstract] [Full Text] [Related]

  • 49. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™).
    Fernando GJP, Hickling J, Jayashi Flores CM, Griffin P, Anderson CD, Skinner SR, Davies C, Witham K, Pryor M, Bodle J, Rockman S, Frazer IH, Forster AH.
    Vaccine; 2018 Jun 18; 36(26):3779-3788. PubMed ID: 29779922
    [Abstract] [Full Text] [Related]

  • 50. Neuraminidase antibodies in serum and nasal washings after immunization by means of live and killed whole virion, split virion and subunit (HA and N) influenza vaccines.
    Kuwert EK, Höher PG, Werner J, Scheiermann N, Thraenhart O, Müller B, Kleber G.
    Dev Biol Stand; 2018 Jun 18; 39():77-83. PubMed ID: 604137
    [Abstract] [Full Text] [Related]

  • 51. Clinical reactions and serologic responses in healthy children aged six to 35 months after two-dose regimens of inactivated A/New Jersey/76 influenza virus vaccines.
    Boyer KM, Cherry JD, Wright PF, Lerman SJ, Gross PA, Foy HM, Taylor JW, Noble GR.
    J Infect Dis; 1977 Dec 18; 136 Suppl():S579-83. PubMed ID: 342630
    [Abstract] [Full Text] [Related]

  • 52. The quantification of the haemagglutinin content of influenza whole virus and Tween-ether split vaccines.
    Johannsen R, Moser H, Hinz J, Friesen HJ, Gruschkau H.
    J Biol Stand; 1983 Oct 18; 11(4):341-52. PubMed ID: 6417143
    [Abstract] [Full Text] [Related]

  • 53. Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high-risk children.
    Allison JE, Glezen WP, Taber LH, Paredes A, Webster RG.
    J Infect Dis; 1977 Dec 18; 136 Suppl():S672-6. PubMed ID: 606790
    [Abstract] [Full Text] [Related]

  • 54. Responses of volunteers to inactivated influenza virus vaccines.
    Jennings R, Potter CW, Massey PM, Duerden BI, Martin J, Bevan AM.
    J Hyg (Lond); 1981 Feb 18; 86(1):1-16. PubMed ID: 7007488
    [Abstract] [Full Text] [Related]

  • 55. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L, Kays SK, Zimmer G, von Messling V.
    J Virol; 2018 Sep 01; 92(17):. PubMed ID: 29925654
    [Abstract] [Full Text] [Related]

  • 56. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.
    Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, Levine M, Katz JM, Ohmit SE.
    J Infect Dis; 2015 Oct 15; 212(8):1191-9. PubMed ID: 25858957
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.